Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Healthcare Biotechnology
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).


TSXV:SBM - Post by User

Sirona Biochem Corp > Time to pull that rabbit out
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(103)
•••
Comment by skiboard09on Sep 29, 2021 2:29pm
157 Views
Post# 33937882

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Time to pull that rabbit out

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Time to pull that rabbit out

"Additionally, as follow-up to the last quarterly report, the company's pharmaceutical partner from the second clinical trial of TFC-1067 has successfully completed due diligence as scheduled. Follow-up discussions are scheduled in September to discuss next steps with the goal of completing a long-term definitive agreement."

so with one day left in September wonder if talks have already happened or it will happen tomorrow. They said DD was complete as scheduled. So how long are we going to have to wait to hear anything. Another 6 months to negotiate a deal?  Think with DD done that a deal would be quick. Thoughts? 


no action in stock indicating a deal is imminent. 
 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities